Cetuximab (Erbitux)
Customize your policy alerts
Sign up for Aetna Policy 0684 alerts
Get alerted when Policy 0684 changes without checking for updates manually.
Monitor payer policy activity
Defines Aetna's medical necessity, precertification, and coverage criteria for cetuximab (Erbitux) for commercial medical plans, including approved disease indications, continuation criteria, and investigational uses.
No material clinical or coverage changes in this revision.
Coverage Criteria for Cetuximab (Erbitux)
Prior Authorization and Documentation
Prior authorization is required for cetuximab (Erbitux) in accordance with Aetna medical policy procedures. Requests must document the specific indication, prior therapies, and relevant biomarker results when applicable (for example, RAS [KRAS and NRAS], BRAF V600E). Prior authorization is also required for use of cetuximab in off‑label combination regimens; when off‑label combinations are requested, provide supporting clinical evidence or rationale and specify the agents and dosing. Documentation should include prior lines of therapy (chemotherapy, targeted agents, or immunotherapy), dates of progression or intolerance, and the treatment plan for the requested cetuximab regimen.
- Prior authorization required for all cetuximab requests.
- Prior authorization required for off‑label combinations; provide clinical justification and supportive evidence.
- Include biomarker test results (eg, KRAS/NRAS, BRAF V600E) when relevant to the indication.
Biomarker and Genomic Testing Requirements
Cetuximab use for colorectal cancer is biomarker‑driven: cetuximab is indicated only for RAS (KRAS and NRAS) wild‑type tumors (not for RAS‑mutant or unknown RAS status). For BRAF V600E‑mutant metastatic colorectal cancer, cetuximab is covered only when used in combination with encorafenib. For KRAS G12C‑positive disease, coverage is limited to combinations with the specified KRAS G12C inhibitors and after prior chemotherapy as outlined in the policy. Provide results from FDA‑approved or validated testing methods to confirm mutation status prior to authorization.
- RAS (KRAS and NRAS) wild‑type confirmation required for routine mCRC cetuximab use.
- BRAF V600E mutation: cetuximab must be used with encorafenib for covered use.
- KRAS G12C mutation: covered only in combination with approved G12C inhibitors and after prior chemotherapy.
Off‑Label Combination Requests
Do not authorize cetuximab when requested for routinely combining with agents listed as experimental/investigational (including panitumumab, erlotinib, gefitinib, bevacizumab, and natural killer cell therapy) outside of clinical trials because safety and effectiveness are not established. The policy notes specific tumor types (eg, pancreatic adenocarcinoma, several listed solid tumors) and combination strategies for which evidence does not support routine coverage—requests for these should be reviewed as investigational and will generally be denied outside a clinical trial.
- Off‑label combinations with agents listed in the Experimental and Investigational section are not supported and will typically be denied.
- If an off‑label combination is requested, submit high‑quality supporting evidence (peer‑reviewed clinical trials or guideline support) and rationale; lack of such evidence may result in denial.
Contraindications and Safety Monitoring
Cetuximab is contraindicated in members with a known hypersensitivity to cetuximab or any component of the formulation. Infusion reactions and cardiopulmonary arrest/sudden death have been reported; infusion should be monitored and cetuximab permanently discontinued for severe infusion reactions. Safety and effectiveness in pediatric and adolescent patients has not been established. Discuss risks with pregnant or breastfeeding patients and document counseling where applicable.
- Do not initiate cetuximab in patients with known hypersensitivity to cetuximab or components.
- Closely monitor for infusion reactions; permanently discontinue for serious infusion reactions.
- Exercise caution in pregnancy or breastfeeding; document counseling.
- Pediatric/adolescent use not established—prior authorization unlikely without robust supportive data.
Avoid Combinations with Excessive Mortality Risk
Avoid regimens or combinations associated with excessive treatment‑related mortality. The policy cites trials in advanced NSCLC where combinations (eg, carboplatin/paclitaxel plus cetuximab and certain investigational antibodies) had excessive grade 5 adverse events and were closed early; such combinations should not be authorized outside controlled trials.
- Do not authorize combinations shown to have excessive grade 5 AEs in clinical trials (provide trial citation if used in justification).
- If prior treatment led to significant toxicity or early deaths in trial data, require strong justification and safety monitoring plan for any similar proposed regimen.
Pancreatic Adenocarcinoma
Routine use of cetuximab in unselected pancreatic adenocarcinoma is not supported by high‑quality evidence (phase III trials and meta‑analyses show no survival or PFS benefit and increased toxicity). Requests for cetuximab in pancreatic adenocarcinoma will generally be denied unless part of a well‑designed clinical trial with a strong scientific rationale.
- Phase III evidence (eg, cetuximab + gemcitabine) demonstrated no clinically significant benefit; routine coverage is not provided.
- For pancreatic cancer, authorize only within clinical trial protocols with appropriate oversight and justification.
Exhaustion of Standard Therapy and Step Therapy Considerations
The policy requires that standard, guideline‑recommended therapies be exhausted or documented as inappropriate or not tolerated before considering cetuximab for many indications (for example, prior chemotherapy for KRAS G12C‑positive colorectal cancer combinations). Where the policy specifies prior lines (eg, progression on EGFR tyrosine kinase inhibitor therapy in NSCLC before EGFR inhibitor combinations), include prior therapy details in the authorization request. The policy does not specify step‑therapy prior authorizations beyond these clinical sequencing requirements.
- Document prior standard therapies and reasons for discontinuation (progression, intolerance, contraindication).
- No separate step‑therapy authorization program is specified in this section beyond clinical sequencing requirements.
- If policy requires prior exposure to a specified agent (eg, prior EGFR TKI in NSCLC), include dates and outcomes of that therapy.
Administrative / Informational Notes
Some portions of this section are informational or administrative (eg, Experimental and Investigational lists, background summaries) and do not themselves establish coverage beyond the policy criteria. Administrative notes or general background do not replace the requirement for prior authorization and documentation of medical necessity.
- Background material and literature summaries are informational only and do not constitute authorization.
- Follow policy coverage criteria and prior authorization rules when making coverage determinations.
Dosing and Combination Regimens
| Regimen | Dosing / Schedule | Indication | Coverage status |
|---|---|---|---|
| Cetuximab (single-agent or in combination with irinotecan or FOLFIRI) | |||
| Weekly: 400 mg/m2 IV loading dose (120-minute infusion) then 250 mg/m2 IV every week (60-minute infusion); Biweekly: 500 mg/m2 IV every 2 weeks (120-minute infusion). Administer 1 hour prior to irinotecan or FOLFIRI. | |||
| Metastatic colorectal cancer — single agent or combined with irinotecan/FOLFIRI per indication | |||
| covered with criteria (see policy for biomarker and line-of-therapy requirements) |
| Regimen | Dosing / Schedule | Indication / Setting | Coverage status |
|---|---|---|---|
| Cetuximab + FOLFIRI | |||
| Cetuximab dosing per schedule: initial 400 mg/m2 IV then 250 mg/m2 weekly (or 500 mg/m2 biweekly); administer 1 hour prior to FOLFIRI | |||
| First-line metastatic colorectal cancer in appropriate patients (see KRAS/NRAS/BRAF biomarker requirements) | |||
| covered with criteria |
| Regimen | Evidence summary | Implication | Coverage status |
|---|---|---|---|
| Bevacizumab combined with cetuximab or panitumumab | |||
| Meta-analysis of randomized trials (4 RCTs, 2,069 patients) found no significant improvement in PFS or OS and no increase in ORR with the addition of bevacizumab to cetuximab/panitumumab-based therapy (Lv et al, 2015) | |||
| Combination not recommended due to lack of demonstrated benefit | |||
| not_covered |
| Regimen | Study phase / dosing | Results / notes | Coverage status |
|---|---|---|---|
| GEMOX (gemcitabine + oxaliplatin) + cetuximab | |||
| Cetuximab 400 mg/m2 loading then 250 mg/m2 weekly with gemcitabine 1000 mg/m2 day 1 and oxaliplatin 100 mg/m2 day 2 every 2 weeks (per phase II trial) | |||
| Phase II in advanced hepatocellular carcinoma: confirmed response rate ~20%, disease stabilization in 40%; randomized trial planned | |||
| experimental |
| Regimen | Dosing / schedule | Study findings | Coverage status |
|---|---|---|---|
| Cetuximab + gemcitabine/platinum | |||
| Cetuximab dosing per standard schedule (400 mg/m2 loading then 250 mg/m2 weekly or 500 mg/m2 biweekly) administered with gemcitabine and platinum per trial protocols | |||
| Randomized phase II (Butts et al) showed partial responses and acceptable toxicity; mixed results across trials with modest or inconsistent benefit | |||
| experimental |
| Regimen | Dosing / schedule | Study observations | Coverage status |
|---|---|---|---|
| Cetuximab + bevacizumab + irinotecan | |||
| Cetuximab 400 mg/m2 loading then 250 mg/m2 weekly given with bevacizumab (5–10 mg/kg q2wk) and irinotecan (dose per protocol) | |||
| Phase II in recurrent GBM reported radiographic responses (34% radiographic response among evaluable patients) but did not demonstrate superiority over bevacizumab/irinotecan alone | |||
| experimental |
| Regimen | Dosing / schedule | Evidence / safety notes | Coverage status |
|---|---|---|---|
| Cetuximab + cisplatin/vinorelbine; Cetuximab + carboplatin/paclitaxel; Cetuximab + gemcitabine/cisplatin | |||
| Cetuximab per standard dosing combined with listed platinum regimens as used in cited trials | |||
| Phase II and randomized phase II trials reported mixed efficacy; some trials suggested modest activity while others showed no clear benefit and, in some combinations, safety concerns or increased toxicity | |||
| investigational |
| Regimen | Dosing / schedule | Indication | Coverage status |
|---|---|---|---|
| Weekly cetuximab dosing regimen (loading then weekly maintenance) | |||
| Initial dose: 400 mg/m2 IV (120-minute infusion) as loading dose; subsequent weekly doses: 250 mg/m2 IV (60-minute infusion) | |||
| Used for unresectable cutaneous squamous cell carcinoma (cetuximab monotherapy trials) and as standard weekly schedule for SCCHN when given with radiation or chemotherapy | |||
| covered with criteria (see policy for specific indications) |
| Example regimen | Dosing / schedule (cetuximab component) | Setting / trial phase | Coverage status |
|---|---|---|---|
| Encorafenib + cetuximab (± alpelisib) | |||
| Cetuximab administered per standard (400 mg/m2 loading then 250 mg/m2 weekly); encorafenib and alpelisib dosed per phase Ib protocol (eg, encorafenib 200 mg) | |||
| Phase Ib dose-escalation in BRAF-mutant mCRC showed confirmed ORR ~18–19% and median PFS ~3.7–4.2 months; tolerable safety profile | |||
| experimental |
Billing and Coding for Cetuximab
| C18.0-C21.8 | Malignant neoplasm of colon, rectosigmoid junction, rectum, anus and anal canal (covered for colorectal indications as specified). |
| C00.0-C08.1, C09.0-C14.8 | Malignant neoplasm of lip, oral cavity, and pharynx (covered for squamous cell carcinoma of the head and neck only). |
| C34.00-C34.92 | Malignant neoplasm of bronchus and lung (non-small cell lung cancer). |
| C44.xx (multiple) | Squamous cell carcinoma of skin (various sites). |
| C60.0-C60.9 | Malignant neoplasm of penis. |
| C15.3-C15.9 | Malignant neoplasm of esophagus (esophageal adenocarcinoma) - not covered. |
| C16.0-C16.9 | Malignant neoplasm of stomach (gastric cancer) - not covered. |
| C22.0-C22.4 | Liver cell carcinoma and related hepatic neoplasms - not covered. |
| C25.0-C25.9 | Malignant neoplasm of pancreas - not covered. |
| C50.011-C50.929 | Malignant neoplasm of breast - not covered. |
| C61 | Malignant neoplasm of prostate - not covered. |
Precertification, Prior Authorization & Documentation
Precertification required
Precertification (preauthorization) of cetuximab (Erbitux) is required for Aetna participating providers and members in applicable plan designs; providers should call or fax the numbers listed and submit a Statement of Medical Necessity (SMN) as indicated.
- Call (866) 752-7021 or fax (888) 267-3277 for precertification.
- SMN precertification forms available via Aetna Specialty Pharmacy Precertification resources.
Prior authorization: confirm indication, prior therapies, and progression
Prior authorization reviews must confirm the requested indication and prior therapies/progression consistent with the policy (for example, metastatic colorectal cancer, head and neck cancer, prior irinotecan exposure where applicable, and tumor KRAS/RAS status).
- For mCRC, prior authorization should document prior irinotecan exposure and progression status consistent with pivotal trial populations.
- For biomarker‑driven indications, confirm KRAS/NRAS (RAS) wild‑type status or other specified mutation-based pathways.
Prior authorization for off‑label combinations: document line of therapy and evidence
When cetuximab is requested in combination regimens that are off‑label or have limited trial evidence, prior authorization must include documentation of line of therapy and supporting clinical evidence from trials or publications.
- Examples include GEMOX + cetuximab in HCC and cetuximab plus platinum/gemcitabine regimens in NSCLC where phase II evidence is limited.
- Specify whether the request is for first‑line, second‑line, or refractory setting and cite supporting study data.
Prior authorization for off‑label indications: include rationale, prior therapies, and evidence
For off‑label indications, prior authorization requests must include the clinical rationale, prior therapies tried, and supporting evidence (clinical trial data, case series, or biomarker data) to justify use outside approved indications.
- Examples of off‑label uses requiring justification include NSCLC, penile cancer, salivary duct carcinoma, and cutaneous SCC in selected settings.
- Provide trial citations or biomarker results (EGFR IHC/FISH, KRAS status) when available to support potential benefit.
Prior authorization for combination regimens: include trial phase, dosing, and safety data
When requesting cetuximab for combination regimens outside standard indications, prior authorization should include trial phase, dosing schema, and safety/efficacy data from the supporting studies.
- Include phase I/II trial details such as recommended phase II dose, dose‑limiting toxicities (DLTs), and observed response rates (e.g., pazopanib 800 mg/day + cetuximab schedule).
- Document how the requested dosing matches the published regimen and any modifications with supporting justification.
Prior authorization — no additional PA codes specified here
This section of the document does not specify additional prior authorization codes or unique administrative prior authorization procedures beyond the general precertification requirement.
Prior authorization — not specified in additional information
No additional prior authorization requirements are specified in the supplemental/administrative portion of this policy.
Biomarker prerequisite: document KRAS/NRAS wild‑type (or specified mutation pathway) for CRC
For colorectal cancer indications, prior documentation of KRAS and NRAS (RAS) wild‑type status (or the specific biomarker-driven mutation pathway requested) is required to establish eligibility per policy.
- Policy requires RAS (KRAS and NRAS) mutation status negative (wild‑type) for standard CRC pathway.
- If BRAF V600E positive, indicate planned combination with encorafenib; if KRAS G12C positive, indicate combination with sotorasib or adagrasib and prior chemotherapy.
Step therapy consideration: document prior standard therapies (irinotecan, platinum chemoradiation)
Prior standard therapies should be documented and considered before cetuximab (for example, prior irinotecan‑based regimens in mCRC and platinum‑based chemoradiation in head & neck cancer).
- For mCRC, document prior irinotecan exposure/progression where applicable.
- For HNSCC, document intolerance or contraindication to platinum‑based chemoradiation if substituting cetuximab with radiation.
Exhaust standard therapy first: document prior established standard treatments
Providers must document that established standard therapies were attempted or are unsuitable before initiating cetuximab in non‑standard settings (e.g., RT with 5‑FU and mitomycin is standard for anal cancer).
- State why standard-of-care options are not appropriate or have failed prior to cetuximab use.
- Cite prior treatment dates, regimens, and response/progression details.
Step therapy / substitution with cisplatin: document why cisplatin is ineligible
When cetuximab is proposed as an alternative to cisplatin‑based concurrent therapy (e.g., with radiotherapy in HNSCC), the prior authorization should state the clinical rationale and document why cisplatin is ineligible.
- Note that meta‑analysis shows inferior outcomes with cetuximab+RT versus cisplatin+RT; document contraindications to cisplatin (e.g., comorbidities) if substitution is requested.
- Include supporting clinical evidence or comorbidity details in the request.
Position after standard therapy: document refractory status and prior lines
Evidence evaluated cetuximab in refractory patients after prior lines of therapy in several tumor types; prior authorization should document prior lines and refractory status when requesting cetuximab in later‑line settings.
- Examples include BRAF‑mutant mCRC after prior therapies and metastatic gastric cancer second‑line combinations.
- Provide prior line counts, dates, and responses to prior regimens.
Precertification and SMN: submit Statement of Medical Necessity
Providers should submit a Statement of Medical Necessity (SMN) as part of the precertification process for cetuximab requests.
- SMN forms available via Aetna Specialty Pharmacy Precertification resources.
- Precertification contact: call (866) 752-7021 or fax (888) 267-3277.
Required clinical documentation: prior irinotecan exposure and progression for mCRC
For metastatic colorectal cancer requests, include documentation of prior irinotecan exposure and progression status consistent with pivotal trial populations when applicable.
- Cite trial population details if relying on evidence from irinotecan‑refractory studies (e.g., response rates and time to progression).
- Include dates and regimens for prior chemotherapy and evidence of progression.
Evidence rationale for off‑label use: document prior therapies, severity, and rationale
When seeking cetuximab for rare or off‑label conditions, include documentation of prior therapies tried, clinical severity, and a clear rationale with supporting evidence to justify non‑approved use.
- Provide case series or trial references if available (e.g., Menetrier's disease reports).
- Describe functional impairment, prior interventions, and why cetuximab is expected to benefit.
Biomarker documentation: include EGFR IHC/FISH and KRAS results
Include biomarker test results (EGFR IHC, EGFR FISH, KRAS status) and prior molecular testing or trial enrollment details when submitting for authorization in biomarker‑selected or investigational scenarios.
- EGFR IHC positivity or EGFR FISH high gene copy number have been used in trials and may be relevant to support off‑label consideration.
- Provide lab reports with test method, date, and result (e.g., EGFR FISH score 5–6 = high FISH).
Document dose escalation and DLTs for combination regimens
For requests involving combination regimens derived from early‑phase trials, document dose‑escalation details, dose‑limiting toxicities (DLTs), and the recommended phase II dose as reported in the supporting study.
- Provide the published dosing schema (e.g., pazopanib 800 mg/day + cetuximab loading 400 mg/m2 then 250 mg/m2 weekly).
- Document observed DLTs and how planned dosing mitigates those risks.
Administrative note: no extra documentation listed here
This administrative portion of the policy does not list additional required documentation for prior authorization; refer to the main policy sections for clinical documentation requirements.
Administrative supplemental: no documentation requirements in this section
Administrative and legal notices in the Additional Information section do not specify clinical documentation requirements for prior authorization.
Contraindications/high‑risk use: hypersensitivity, pediatric, pregnancy/breastfeeding
Requests for cetuximab that involve hypersensitivity to cetuximab, use in pediatric/adolescent patients, or in pregnant/breastfeeding members without documented risk/benefit discussion are at risk for denial.
- Erbitux should not be used in members with hypersensitivity to cetuximab or any component.
- Safety/effectiveness in pediatric/adolescent patients is not established; pregnancy/breastfeeding requires documented risk/benefit discussion.
Denial risk: excessive treatment‑related mortality in prior trials
Trials reporting excessive treatment‑related mortality or lack of efficacy (for example, the Hanna et al. NSCLC trial closed early for excessive grade 5 AEs) support denial for similar high‑risk combinations without demonstrated benefit.
- Hanna et al (2015) trial closed early due to an excessive number of grade 5 adverse events and lacked efficacy signal for certain combinations.
- Provide safety data and rationale if requesting coverage for regimens with similar safety concerns.
Denial risk: pancreatic adenocarcinoma — lack of efficacy
Requests for cetuximab to treat pancreatic adenocarcinoma in unselected patients risk denial because randomized phase III trials and a meta‑analysis showed no survival or PFS benefit and similar or increased toxicity.
- Philip et al (2007) phase III trial (n=735) showed no significant OS or PFS benefit adding cetuximab to gemcitabine.
- Systematic review/meta‑analysis (Forster et al 2020) of 4 RCTs (924 patients) found no OS/PFS/objective response benefit and similar or increased toxicity.
Denial risk: urothelial carcinoma combinations showed increased toxicity/no outcome benefit
Addition of cetuximab to gemcitabine/cisplatin in urothelial carcinoma increased adverse events without improving outcomes; requests for this combination in unselected UC patients may be denied.
- Randomized phase II trial (Hussain et al. 2014) showed similar ORR, no PFS/OS benefit, and more grade 3/4 AEs (and some grade 5 events) with GC + cetuximab.
- Provide biomarker‑selected evidence if arguing for coverage in specific UC subgroups.
Biomarker Testing and Documentation Requirements
Biomarker documentation required: include EGFR IHC, EGFR FISH, KRAS and molecular testing reports
When submitting for authorization, include EGFR IHC, EGFR FISH, KRAS status, and molecular testing results when relevant to support biomarker‑driven or investigational requests.
- EGFR FISH high (score 5–6) associated with longer PFS in one NSCLC trial (SWOG 0342).
- Include specific assay results, dates, and interpretation in the submission.
Indication by Line of Therapy
first-line
Line of therapy determined by indication and trial evidence
subsequent
Requires prior therapy per indication
first-line and second-line
Refer to indication‑specific criteria
first-line | second-line
Line varies by published trial
first-line | salvage
Evidence mixed across studies
second-line
Often after exhaustion of standard therapies
Background and Evidence Summary
Cetuximab dosing follows the prescribed regimens: an initial loading dose of 400 mg/m2 IV followed by 250 mg/m2 weekly or 500 mg/m2 biweekly as specified by indication and regimen. Specific administration schedules depend on the tumor type and combination regimen.
inv-10 (supporting context): Head & neck evidence comparison and trial outcomes summarized
Li et al (2023) and retrospective series summarized
Evidence summaries for pancreatic adenocarcinoma demonstrate lack of efficacy: a large phase III trial of gemcitabine plus cetuximab failed to show survival or PFS benefit, and a meta‑analysis of randomized trials found no OS/PFS/objective response advantage and similar or higher toxicity. These high‑quality randomized data support excluding routine cetuximab use in unselected pancreatic cancer patients.
Definitions and Key Terms
Policy Dates & Revision History
This supplemental administrative section provides links to the policy's history and definitions and includes Aetna's legal and contact information. It does not itself change coverage criteria or list clinical exclusions.
This supplemental portion does not specify prior authorization procedures. The policy history panel documents the last review date 02/02/2024, the effective date 04/13/2004, and the next review date 09/26/2024, but explicit prior authorization codes or processes are provided elsewhere in the main policy text.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.